1. Home
  2. AIN vs PHVS Comparison

AIN vs PHVS Comparison

Compare AIN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Albany International Corporation

AIN

Albany International Corporation

HOLD

Current Price

$56.73

Market Cap

1.7B

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$27.52

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIN
PHVS
Founded
1895
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
AIN
PHVS
Price
$56.73
$27.52
Analyst Decision
Hold
Buy
Analyst Count
4
10
Target Price
$60.25
$41.80
AVG Volume (30 Days)
229.2K
189.1K
Earning Date
04-29-2026
05-12-2026
Dividend Yield
2.00%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,054,132,000.00
N/A
Revenue This Year
$1.20
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.29
N/A
52 Week Low
$41.15
$11.66
52 Week High
$73.00
$29.85

Technical Indicators

Market Signals
Indicator
AIN
PHVS
Relative Strength Index (RSI) 58.90 51.50
Support Level $54.15 $24.55
Resistance Level $60.43 $28.06
Average True Range (ATR) 1.67 1.34
MACD 0.65 0.09
Stochastic Oscillator 97.22 51.22

Price Performance

Historical Comparison
AIN
PHVS

About AIN Albany International Corporation

Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: